Miles S, Fordham R, Mills C, Valovirta E, Mugford M
School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, UK.
Allergy. 2005 Aug;60(8):996-1003. doi: 10.1111/j.1398-9995.2005.00868.x.
Both immunoglobulin E (IgE)-mediated food allergy and food intolerance can lead to many changes in personal behaviour and health care resource use which have important economic consequences. These costs will impact directly, indirectly and intangibly on both individuals and society in general. It is important to measure the cost of illness (COI) of food allergy as a first step in developing and evaluating measures to reduce and control the burden of illness. This paper outlines a framework for assessing COI of food allergy from different viewpoints. It offers a structure for identifying the different cost impacts on allergic and nonallergic consumers, food producers and society as a whole, and for scoping, measurement and valuation of relevant costs. Within this structure, the existing literature is reviewed. This review illustrates the lack of information and clear methodology for assessing costs of food allergy. The paper concludes that there is a need for a more structured research programme to generate data essential for future evaluations of procedures and technologies for the diagnosis, treatment and management of food allergy.
免疫球蛋白E（IgE）介导的食物过敏和食物不耐受都会导致个人行为和医疗资源使用方面的诸多变化，这些变化会产生重要的经济后果。这些成本将直接、间接且无形地影响个人和整个社会。衡量食物过敏的疾病成本（COI）很重要，这是制定和评估减轻及控制疾病负担措施的第一步。本文概述了一个从不同视角评估食物过敏疾病成本的框架。它提供了一个结构，用于识别对过敏和非过敏消费者、食品生产商以及整个社会的不同成本影响，以及对相关成本进行界定、衡量和估值。在此结构内，对现有文献进行了综述。该综述表明，在评估食物过敏成本方面缺乏信息和明确的方法。本文得出结论，需要一个更具结构性的研究计划来生成必要数据，以便未来对食物过敏的诊断、治疗和管理程序及技术进行评估。
